abstract |
The present disclosure relates to a system of two engineered receptors each having a ligand binding domain designed entirely in a target cell identified by loss of heterozygosity and used to treat a disease or disorder, such as cancer. The present disclosure provides immune cells expressing two engineered receptors, methods of making them, and polynucleotides and vectors encoding the same. |